D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
KYMR holding history
Kymera Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
KYMR overviewAll 13F holders of KYMRFull Q2 2026 holdings
- Shares (Q2 2026)
- 2,800
- Value
- $321.1K
- % of portfolio
- <0.1%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,800 | $321.1K | <0.1% | +2,800 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −82,578−100.0% | Sold out | Holders |
| Q4 2024 | 82,578 | $3.32M | <0.1% | −105,619−56.1% | Reduced | Holders |
| Q3 2024 | 188,197 | $8.91M | <0.1% | −107,375−36.3% | Reduced | Holders |
| Q2 2024 | 295,572 | $8.82M | <0.1% | +227,810+336.2% | Added | Holders |
| Q1 2024 | 67,762 | $2.72M | <0.1% | +67,762 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −27,032−100.0% | Sold out | Holders |
| Q1 2023 | 27,032 | $801.0K | <0.1% | +13,553+100.5% | Added | Holders |
| Q4 2022 | 13,479 | $336.4K | <0.1% | +2,662+24.6% | Added | Holders |
| Q3 2022 | 10,817 | $235.0K | <0.1% | +10,817 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −14,645−100.0% | Sold out | Holders |
| Q1 2021 | 14,645 | $569.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.